Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Thomas Jefferson University
Takeda
Tempus AI
Incyte Corporation
Actym Therapeutics, Inc.
Taiho Oncology, Inc.
Bolt Biotherapeutics, Inc.
Sanofi
Washington University School of Medicine
University of Virginia
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
NRG Oncology
NextCure, Inc.
Black Diamond Therapeutics, Inc.
Elevation Oncology
Turnstone Biologics, Corp.
Deciphera Pharmaceuticals, LLC
Aminex Therapeutics, Inc.
National Cancer Institute (NCI)
NantCell, Inc.
Washington University School of Medicine
Pfizer
Ikena Oncology
Ikena Oncology
Cambridge University Hospitals NHS Foundation Trust
CytomX Therapeutics
Atreca, Inc.
Fusion Pharmaceuticals Inc.
Biocept, Inc.
Pfizer
pharmaand GmbH
Fate Therapeutics
Hoffmann-La Roche
West Virginia University
Incyte Corporation
University of Maryland, Baltimore
Ipsen
Silverback Therapeutics
Stanford University
Centre Hospitalier Universitaire Vaudois
MacroGenics
Novartis
National Institutes of Health Clinical Center (CC)
ADC Therapeutics S.A.
Advanced Accelerator Applications
Seagen Inc.
AIDS Malignancy Consortium
National Institutes of Health Clinical Center (CC)